



## Fosamprenavir Calcium Tablets

|                         |                   |
|-------------------------|-------------------|
| <b>Type of Posting</b>  | Revision Bulletin |
| <b>Posting Date</b>     | 25-Aug-2023       |
| <b>Official Date</b>    | 1-Sep-2023        |
| <b>Expert Committee</b> | Small Molecules 1 |

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 1 Expert Committee has revised the Fosamprenavir Calcium Tablets monograph. The purpose of this revision is to add *Dissolution Test 2* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s). *Labeling* information has been incorporated to support the inclusion of *Dissolution Test 2*.

- *Dissolution Test 2* was validated using the InertSil C8-3 brand of column with L7 packing. The typical retention time for fosamprenavir is about 5 min.

The Fosamprenavir Calcium Tablets Revision Bulletin supersedes the currently official monograph

Should you have any questions, please contact Yanyin Yang, Senior Scientist II (301-692-3623 or [yanyin.yang@usp.org](mailto:yanyin.yang@usp.org)).